Sarepta Therapeutics Q3 2026 Earnings Date & Estimates

Sarepta Therapeutics (NASDAQ:SRPT) (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs use RNA-based technologies, gene therapy and other genetic approaches to address the underlying causes of serious neuromuscular disorders.

The company’s primary focus is Duchenne muscular dystrophy (DMD), a progressive genetic disease that causes muscle weakness and loss of function. Sarepta markets Exondys 51 (eteplirsen), Vyondys 53 (golodirsen) and Amondys 45 (casimersen), RNA-based therapies designed to help certain patients produce a shortened but functional form of dystrophin. Sarepta also markets Elevidys (delandistrogene moxeparvovec), a gene therapy intended to deliver a micro-dystrophin gene to muscle cells in eligible patients with DMD.

Sarepta’s pipeline includes additional investigational genetic medicines for neuromuscular conditions, including limb-girdle muscular dystrophies and other rare diseases. The company was formerly known as AVI BioPharma and adopted the Sarepta Therapeutics name in 2012. Sarepta is headquartered in Cambridge, Massachusetts, and its medicines and development programs serve patients through regulatory and commercial activities in the United States and selected international markets. Doug Ingram has served as the company’s president and chief executive officer since 2017.